Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

Blood (2023) 142 (Supplement 1): 4977.

https://doi.org/10.1182/blood-2023-173727

Published: 2023

Journal Articles

A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma

Valentin Daguerre, Elisabeth Daguenet, Nicolas Jacquet-Francillon, Ludovic Fouillet, Ugo Thévenet, Maxime Bonjour, Herve Ghesquieres, Imran Ahmad, Jerome Cornillon

Blood (2023) 142 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2023-181710

Published: 2023

Journal Articles

Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies

Filippo Milano, Guy Sauvageau, Gabrielle Thauvette, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Laura C Roberts, Laurel Thur, Jenna B Pedersen, Ann Dahlberg, Sandra Cohen

Blood (2023) 142 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2023-187446

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2023-184995

Published: 2023

Journal Articles

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Camille Gauvin, Imran Ahmad, Luigina Mollica, Sandra Cohen, Olivier Veilleux, Sylvie Lachance, Isabelle Fleury

Blood (2023) 142 (Supplement 1): 6150.

https://doi.org/10.1182/blood-2023-183021

Published: 2023

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas L. Kiss, Sylvia Lachance, Denis-Claude Roy, Jean Roy, Guy Sauvageau, Olivier Veilleux, Imran Ahmad

Blood (2022) 140 (Supplement 1): 7759–7760.

https://doi.org/10.1182/blood-2022-157107

Published: 2022

Journal Articles

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Sandra Cohen, Nadia M. Bambace, Imran Ahmad, Linda J. Burns, Jean Roy, Silvy Lachance, Léa Bernard, Jean-Sébastien Delisle, Denis-Claude Roy, Thomas L. Kiss, Olivier Veilleux, Mei-Jie Zhang, Xiao-Ying Tang, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 1610–1612.

https://doi.org/10.1182/blood-2022-160417

Published: 2022

Journal Articles

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139598

Published: 2020

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

A Nationwide Analysis of Trends in in-Hospital Mortality in Patients with Sickle Cell Disease from 2000 to 2014

Imran Ahmad, MD MPH, Muhammad Sarfraz Nawaz, MD, Girindra Ghanshyam Raval, MD, Achuta Kumar Guddati, MD PhD

Blood (2018) 132 (Supplement 1): 4808.

https://doi.org/10.1182/blood-2018-99-116373

Published: 2018

Journal Articles

Correlation of Serum Ferritin Levels with Liver Iron Concentration By MRI Measurement in Sickle Cell Patients with Transfusional Iron Overload

Germame Ajebo, MD, Abhishek A. Mangaonkar, MD, Imran Ahmad, MD MPH, Nadine Barrett, MSN, Leigh Wells, MSN, Niren Patel, MBBS, Hongyan Xu, PhD, Abdullah Kutlar, MD

Blood (2018) 132 (Supplement 1): 4926.

https://doi.org/10.1182/blood-2018-99-119597

Published: 2018

Journal Articles

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Blood (2018) 132 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2018-99-110188

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Miriam Marquis, PhD, Cyrielle Beaubois, Vincent-Philippe Lavallee, MD, Michal Abrahamowicz, PhD, Coraline Danieli, PhD, Sébastien Lemieux, PhD, Imran Ahmad, MD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephen B Ting, MD PhD, Shaun Fleming, MBBS(Hons) FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, William Grey, PhD, David Grimwade, MD PhD, Robert K. Hills, DPhil, Paresh Vyas, MD PhD, Nigel H. Russell, MD, Guy Sauvageau, MD, PhD, Josee Hebert, MD

Blood (2017) 130 (Supplement 1): 1402.

https://doi.org/10.1182/blood.V130.Suppl_1.1402.1402

Published: 2017

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Richard LeBlanc, MDFRCPC, Imran Ahmad, MD M.Sc., Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD, Jean-Sébastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MDFRCPC, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2017) 130 (Supplement 1): 4556.

https://doi.org/10.1182/blood.V130.Suppl_1.4556.4556

Published: 2017

Journal Articles

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Magalie Tardif, MSc, MD Student, Imran Ahmad, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Lambert Busque, MD PhD FRCPC, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Isabelle Fleury, MD, Silvy Lachance, MD, Luigina Mollica, MD PhD, Céline Nkoué, MD, Denis-Claude Roy, MD, Jean Roy, MD, Sandra Cohen, MD

Blood (2016) 128 (22): 4677.

https://doi.org/10.1182/blood.V128.22.4677.4677

Published: 2016

Journal Articles

Evaluation of the Impact of Hematopoietic Stem Cell Transplant on the Quality of Life of Elderly Patients Treated for Lymphoma

Christopher Lemieux, MD, Nadia M. Bambace, MD, Jean Roy, MD, Sandra Cohen, MD, Imran Ahmad, MD, Lea Bernard, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD

Blood (2016) 128 (22): 4788.

https://doi.org/10.1182/blood.V128.22.4788.4788

Published: 2016

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

NARROW

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma

Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

A Nationwide Analysis of Trends in in-Hospital Mortality in Patients with Sickle Cell Disease from 2000 to 2014

Correlation of Serum Ferritin Levels with Liver Iron Concentration By MRI Measurement in Sickle Cell Patients with Transfusional Iron Overload

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Evaluation of the Impact of Hematopoietic Stem Cell Transplant on the Quality of Life of Elderly Patients Treated for Lymphoma

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only